Expression and prognostic relevance of annexin A3 in prostate cancer.
暂无分享,去创建一个
Martin Schostak | Helmut Klocker | Hartwig Huland | Thorsten Schlomm | Ronald Simon | Guido Sauter | André Schrattenholz | H. Klocker | G. Sauter | J. Köllermann | T. Schlomm | R. Simon | H. Huland | G. Schwall | C. von Eichel-Streiber | A. Schrattenholz | M. Schostak | Jens Köllermann | H. Bang | H. Bang | Wigbert Berg | Holger Bang | Gerhard P. Schwall | Christoph von Eichel-Streiber | Wigbert Berg
[1] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[2] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[3] M. Graefen,et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. , 2002, European urology.
[4] Rong-Fong Shen,et al. Identification and proteomic profiling of exosomes in human urine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] F. Waldman,et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. , 1995, Human pathology.
[6] S. Nilsson,et al. Prostasome‐derived proteins capable of eliciting an immune response in prostate cancer patients , 2006, International journal of cancer.
[7] S. Pentyala,et al. Prostasomes: Current concepts , 2000, The Prostate.
[8] S. Moss,et al. Annexins: linking Ca2+ signalling to membrane dynamics , 2005, Nature Reviews Molecular Cell Biology.
[9] T C Gasser,et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.
[10] K. Pienta,et al. Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.
[11] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[12] P. Härkönen. Editorial comment on: expression and prognostic relevance of annexin A3 in prostate cancer. , 2008, European Urology.
[13] Qingqing Wang,et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells , 2007, Journal of Cancer Research and Clinical Oncology.
[14] G. Ronquist,et al. Antiprostasome antibody titres in benign and malignant prostate disease. , 2005, Anticancer research.
[15] Sung Goo Park,et al. Annexin A3 is a potential angiogenic mediator. , 2005, Biochemical and biophysical research communications.
[16] C. Roehrborn,et al. Gleason Scores from Prostate Biopsies Obtained with 18-Gauge Biopsy Needles Poorly Predict Gleason Scores of Radical Prostatectomy Specimens , 1998, European Urology.
[17] D. Bostwick,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.
[18] D. Gleason. Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. , 1996, Urology.
[19] Sascha Keller,et al. Exosomes: from biogenesis and secretion to biological function. , 2006, Immunology letters.
[20] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[21] A. Lu,et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.
[22] H. Klocker,et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3 , 2007, Proteomics.
[23] Holger Moch,et al. Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology? , 2001, Advances in anatomic pathology.
[24] A. Larsson,et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. , 2006, Urologic oncology.
[25] J. Blasko,et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.
[26] M. Lykourinas,et al. Gleason Scores from Prostate Biopsies Obtained with 18-Gauge Biopsy Needles Poorly Predict Gleason Scores of Radical Prostatectomy Specimens , 1999, European Urology.
[27] G. Multhoff,et al. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. , 2005, Exercise immunology review.
[28] Peter C Albertsen,et al. Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. , 2002, Surgical oncology.
[29] L. Zitvogel,et al. From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. , 2002, Current opinion in molecular therapeutics.
[30] Pierre I Karakiewicz,et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. , 2003, European urology.
[31] T. Stamey,et al. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA , 2004, BJU international.